SAB Biotherapeutics, Inc.
SABS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $2 | $24 | $61 |
| % Growth | -40.9% | -90.6% | -60.7% | – |
| Cost of Goods Sold | $5 | $4 | $3 | $2 |
| Gross Profit | -$3 | -$2 | $21 | $59 |
| % Margin | -262.4% | -67.3% | 86.2% | 97.3% |
| R&D Expenses | $30 | $17 | $36 | $57 |
| G&A Expenses | $0 | $24 | $16 | $17 |
| SG&A Expenses | $9 | $24 | $16 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$4 | -$3 | -$2 |
| Operating Expenses | $39 | $37 | $50 | $73 |
| Operating Income | -$43 | -$38 | -$29 | -$13 |
| % Margin | -3,244.9% | -1,700.5% | -121% | -22% |
| Other Income/Exp. Net | $9 | -$4 | $10 | -$4 |
| Pre-Tax Income | -$34 | -$42 | -$19 | -$17 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$34 | -$42 | -$19 | -$17 |
| % Margin | -2,579% | -1,884.5% | -78.4% | -28.2% |
| EPS | -3.68 | -7.64 | -4.31 | -3.94 |
| % Growth | 51.8% | -77.3% | -9.4% | – |
| EPS Diluted | -3.68 | -7.64 | -4.31 | -6.3 |
| Weighted Avg Shares Out | 9 | 6 | 4 | 4 |
| Weighted Avg Shares Out Dil | 9 | 6 | 4 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5 | $4 | $3 | $2 |
| EBITDA | -$29 | -$38 | -$15 | -$15 |
| % Margin | -2,192.5% | -1,703.1% | -63.3% | -25% |